A blend nickname helps you find a catalog page, but it does not define a complete formulation. GLOW and KLOW requests should identify the exact listing and component schedule. Similar totals do not establish equivalent material, and a familiar blend name should not replace the laboratory’s written specification.
Start with the exact catalog version
As reviewed on 5 October 2026, the GLOW overview lists 70 mg and the KLOW overview lists 80 mg. The separate 70 mg GLOW listing also specifies ten vials. The overview pages ask buyers to confirm packaging. These are catalog statements, not a stock reservation or independent measurement of a supplied lot. Save the page URL and selected option. If another version is offered, ask for a separate component schedule.
Compare components without filling unknown fields
The table transcribes only the relevant catalog information. The detailed GLOW listing states GHK-Cu 50 mg, BPC-157 10 mg and a TB-500-designated component 10 mg. The overview pages do not publish the same component-by-component amounts. Missing values remain questions, not numbers to reconstruct from another seller’s recipe. Ask whether the figures represent nominal inputs, specified delivered amounts or analytical results.
| Listing | Published component information | Quantity / packaging |
|---|---|---|
| GLOW overview | GHK-Cu, BPC-157 and TB-500 designation; amounts need confirmation | 70 mg; confirm pack format |
| Detailed 70 mg GLOW | GHK-Cu 50 mg; BPC-157 10 mg; TB-500 designation 10 mg | 70 mg × 10 vials |
| KLOW overview | GHK-Cu, BPC-157, TB-500 designation and KPV; amounts need confirmation | 80 mg; confirm pack format |
Resolve identity before comparing amounts
Ask which exact peptide identity the TB-500 designation represents, including full-length versus fragment identity. For GHK-Cu, request the proposed copper-complex description. A quantity beside a short name does not resolve either issue. Keep the stated basis next to every amount. Adding declared input quantities checks formulation arithmetic; it cannot establish measured content in a finished vial. An agreed version should show how each open identity question was resolved.
Separate component records from finished-blend evidence
An input-material document answers a different question from a report on the final mixture. Record the sample tested, identities addressed and analytical coverage. Do not combine component purity percentages into a purity claim for the blend. If no lot is assigned, label the supplied report as a reference example. Ask which documents will accompany the actual mixture and let the laboratory reviewer identify the evidence needed for the project.
Request a formulation version, not only a nickname
The practical output is a dated component schedule accepted in writing. Keep pack count outside the formulation schedule so ten vials cannot be confused with the amount in one vial. A revised quote should accept your schedule or mark proposed changes. Literature on individual components does not validate this mixture’s compatibility, stability or biological behavior. This comparison is not a use recommendation or a claim of equivalence between versions.
Before closing this review
- Every component has an identity or an open question.
- Overview and detailed versions have not been merged.
- Input reports are not marked as finished-blend evidence.
- The agreed schedule and packaging are retained.
Continue with GLOW blend overview; KLOW blend overview; 70 mg GLOW component listing. Save the relevant product or guide link alongside the written response so another reviewer can reconstruct the decision.
Editorial scope: research-material procurement and document review. Not medical guidance, dosing instructions or a claim of suitability for human use. Requirements and availability must be confirmed for the quoted material.
